BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jin XF, Spöttl G, Maurer J, Nölting S, Auernhammer CJ. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers (Basel) 2021;13:1485. [PMID: 33807122 DOI: 10.3390/cancers13061485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Eleveld TF, Vernooij L, Schild L, Koopmans B, Alles LK, Ebus ME, Dandis R, van Tinteren H, Caron HN, Koster J, van Noesel MM, Tytgat GAM, Eising S, Versteeg R, Dolman MEM, Molenaar JJ. MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma. Front Oncol 2023;13:1130034. [PMID: 36895472 DOI: 10.3389/fonc.2023.1130034] [Reference Citation Analysis]
2 Wu H, Yu Z, Liu Y, Guo L, Teng L, Guo L, Liang L, Wang J, Gao J, Li R, Yang L, Nie X, Su D, Liang Z. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract. Cancer Commun (Lond) 2022;42:1367-86. [PMID: 36264285 DOI: 10.1002/cac2.12372] [Reference Citation Analysis]
3 Chilamakuri R, Agarwal S. Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth. Current Oncology 2022;29:6508-6522. [DOI: 10.3390/curroncol29090512] [Reference Citation Analysis]
4 de Sousa MJ, Gervaso L, Meneses-Medina MI, Spada F, Abdel-Rahman O, Fazio N. Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside. Curr Oncol Rep 2022. [PMID: 35262877 DOI: 10.1007/s11912-022-01251-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]